1327 related articles for article (PubMed ID: 31351185)
1. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
4. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease.
Dutta D; Kundu M; Mondal S; Roy A; Ruehl S; Hall DA; Pahan K
Neurobiol Dis; 2019 Dec; 132():104575. PubMed ID: 31445159
[TBL] [Abstract][Full Text] [Related]
5. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
6. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
8. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
De Lella Ezcurra AL; Chertoff M; Ferrari C; Graciarena M; Pitossi F
Neurobiol Dis; 2010 Mar; 37(3):630-40. PubMed ID: 19969084
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease.
Gorelenkova Miller O; Behring JB; Siedlak SL; Jiang S; Matsui R; Bachschmid MM; Zhu X; Mieyal JJ
Antioxid Redox Signal; 2016 Dec; 25(18):967-982. PubMed ID: 27224303
[TBL] [Abstract][Full Text] [Related]
10. Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease.
Gao JP; Sun S; Li WW; Chen YP; Cai DF
Neurosci Bull; 2008 Jun; 24(3):133-42. PubMed ID: 18500385
[TBL] [Abstract][Full Text] [Related]
11. Silibinin attenuates MPP⁺-induced neurotoxicity in the substantia nigra in vivo.
Jung UJ; Jeon MT; Choi MS; Kim SR
J Med Food; 2014 May; 17(5):599-605. PubMed ID: 24660866
[TBL] [Abstract][Full Text] [Related]
12. Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.
Beier EE; Neal M; Alam G; Edler M; Wu LJ; Richardson JR
Neurobiol Dis; 2017 Dec; 108():115-127. PubMed ID: 28823928
[TBL] [Abstract][Full Text] [Related]
13. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
14. Th17 Cells Induce Dopaminergic Neuronal Death via LFA-1/ICAM-1 Interaction in a Mouse Model of Parkinson's Disease.
Liu Z; Huang Y; Cao BB; Qiu YH; Peng YP
Mol Neurobiol; 2017 Dec; 54(10):7762-7776. PubMed ID: 27844285
[TBL] [Abstract][Full Text] [Related]
15. Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression.
Wang Y; Wang Q; Yu R; Zhang Q; Zhang Z; Li H; Ren C; Yang R; Niu H
Aging (Albany NY); 2020 Jul; 12(14):14232-14243. PubMed ID: 32706757
[TBL] [Abstract][Full Text] [Related]
16. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.
Costa T; Fernandez-Villalba E; Izura V; Lucas-Ochoa AM; Menezes-Filho NJ; Santana RC; de Oliveira MD; Araújo FM; Estrada C; Silva V; Costa SL; Herrero MT
J Neuroimmune Pharmacol; 2021 Jun; 16(2):390-402. PubMed ID: 32564332
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss.
Liu Z; Chen HQ; Huang Y; Qiu YH; Peng YP
Brain Behav Immun; 2016 Jan; 51():131-143. PubMed ID: 26254549
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
19. The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration.
Tu D; Gao Y; Yang R; Guan T; Hong JS; Gao HM
J Neuroinflammation; 2019 Dec; 16(1):255. PubMed ID: 31805953
[TBL] [Abstract][Full Text] [Related]
20. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
Sriram K; Miller DB; O'Callaghan JP
J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
